Vimarsana
Biggest News Aggregation in the World

History Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In History Study Today - Breaking & Trending Today

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome - Vimarsana News

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

REDWOOD CITY, Calif., April 30, 2024 -- Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the...

Why Is Benitec Biopharma Stock Trading Higher On Thursday? - Benitec Biopharma (NASDAQ:BNTC) - Vimarsana News

Why Is Benitec Biopharma Stock Trading Higher On Thursday? - Benitec Biopharma (NASDAQ:BNTC)

Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces interim findings and $40 million PIPE financing.

Eli Lilly - Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting - Vimarsana News

Eli Lilly - Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

INDIANAPOLIS - Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company , today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated...

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65 - Vimarsana News

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65

-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women ---- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a cli...

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting - Vimarsana News

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...